Israel Hodish, MD, PhD is an assistant professor in the Division of Metabolism, Endocrinology & Diabetes (MEND), University of Michigan Health System. Dr. Hodish received his bachelor and MD degrees at the Hadassah Medical School at the Hebrew University, Jerusalem, Israel, in 1996. Following residency training in internal medicine, Dr. Hodish completed his PhD degree in 2006 in the field of anti-angiogenic gene therapy at the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Dr. Hodish performed his fellowship training at the Division of Metabolism, Endocrinology and Diabetes, University of Michigan, and joined the faculty in 2007.

Dr. Hodish's area of greatest clinical expertise is in the management of endocrine diseases, particularly beta-cell related diseases, including diabetes and hypoglycemia.

Dr. Hodish is the principal investigator of a diabetes research laboratory at the Brehm Center for Diabetes Research. His lab focuses on identifying and mitigating early beta-cell dysfunction in pre-diabetes. His ultimate goal is to prevent further damage and destruction of beta-cells by glycotoxicity, and to avoid frank diabetes, which is frequently difficult to manage and is linked with a poorer prognosis. His laboratory is funded by public research support from the National Institutes of Health.

Dr. Hodish is a co-founder of Hygieia Inc., located in Ann Arbor, Michigan. The company has created a novel system for accessible, safe, and effective insulin therapy. This system was designed to circumvent the main impediment in insulin management, namely lack of time and expertise in providing frequent insulin dosage adjustments.